Drug Pipeline

Therapeutic Development Portfolio

Leveraging AI-identified targets across multiple disease areas to advance novel drug candidates

Indication

Code

Partner

Modality
(Focus Area)

Target Identification

Data-driven target discovery

Multi-omics DB validation

Protein-level (MS) validation

Discovery

in vitro

in vivo

Hit

Lead

Preclinical

Clinical

Autoimmune Disease

BIMM-1

Small molecule (Autoimmune diseases / STAT3-driven cancers)

Autoimmune Disease

BIMM-8

Small molecule (Autoimmune diseases)

Autoimmune Disease

BIMM-9

Undisclosed

Small molecule (Autoimmune disorders)

Anti-Cancer

BIMM-10

Undisclosed

Biologics (Solid tumors)

Metabolic Disease

BIMM-6

Small molecule (Liver fibrosis / cirrhosis)

Completed

In Progress

Future